Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2021-05-31 Interim / Quarterly Rep…
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience Q1 Company Update
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly update for Arctic Bioscience covering Q1 2021. It includes substantive financial data (Revenues, EBITDA, CAPEX, Cash holdings) and a detailed management discussion of operations, clinical trials, and outlook. It is not merely an announcement of a report, nor is it a short certification. It fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial and operational performance for a period shorter than a full fiscal year. Q1 2021
2021-05-31 English
Arctic Bioscience Q1 Company Update
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Arctic Bioscience Q1 Company Update' and provides a comprehensive overview of the company's performance for the first quarter of 2021. It includes specific financial data (Revenues, Gross profit, EBITDA, CAPEX, Cash holdings) for Q1 2021, alongside operational updates, management commentary, and outlook. Since it contains substantive financial statements and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2021
2021-05-31 English
Arctic Bioscience - Presentation at ABG Sundal Collier Life Science Summit
Investor Presentation Classification · 98% confidence The document text consists of slides detailing company highlights, business strategy, clinical trial results for a psoriasis drug candidate (HRO350), market opportunity analysis, and management team profiles. The title explicitly states it is from the 'ABGSC Life Science Summit 25th May 2021'. This format—a presentation given at an investor conference—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing (like 10-K or IR), nor is it a short announcement of a report (RPA/RNS).
2021-05-25 English
Arctic Bioscience - Presentation at ABG Sundal Collier Life Science Summit
Investor Presentation Classification · 95% confidence The document is titled "Arctic Bioscience - Presentation at ABG Sundal Collier Life Science Summit". It explicitly states that the company participated in a summit and that the "Presentation material attached." This indicates the document itself is an announcement about a presentation, rather than the full presentation or a formal regulatory filing like a 10-K or IR. Since it announces the availability of presentation material for an investor-focused event (Life Science Summit), the most appropriate classification is Investor Presentation (IP). However, given the very short length (1931 chars) and the explicit statement that the material is attached, it strongly aligns with the 'Menu vs Meal' rule, suggesting it is an announcement of the presentation material rather than the material itself. If the material was attached, this announcement serves as a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since 'IP' is defined as the detailed presentation itself, and this is just the announcement stating the material is attached, RPA is a strong candidate. However, because the content *is* about an investor presentation, and IP is the closest thematic fit, I will check the definitions again. IP is 'Detailed presentation for investors focusing on financials, strategy, and market position.' RPA is 'Announcement regarding the timing, release, or publication of company reports'. Since the core content is the presentation material being shared at an investor event, and the document is short and points to the material, it functions as an announcement of investor material. Given the options, if the actual presentation slides were not provided, this announcement is best categorized as an Investor Presentation (IP) if we assume the attached material is the presentation, or RPA if we strictly follow the 'Menu vs Meal' rule for short announcements. Since the document explicitly mentions the presentation content (goals, strategy, priorities) and attaches the material, IP is the intended classification for the *subject matter*. If the attached material is the presentation, this is the announcement of it. Given the context of financial databases, documents announcing investor presentations are often tagged as IP. I will classify it as IP, acknowledging the announcement nature, as the core subject is the investor presentation.
2021-05-25 English
New drug candidate for normal brain development in extremely premature infants
Regulatory Filings Classification · 97% confidence The document describes a research collaboration between Arctic Bioscience and SMERUD to develop a new drug candidate based on phospholipid esters from herring roe for extremely premature infants. It details the scientific rationale, the planned development steps (including applying for orphan designation), quotes management, and outlines the collaboration partners. This content is characteristic of an announcement regarding a new strategic development, partnership, or pipeline update, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a formal capital structure change (CAP). Since it is a significant business development announcement detailing a new drug pipeline focus, it fits best under a general business/investor relations announcement category. Given the provided options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standard announcements that don't fit the specific financial report or corporate action codes, although 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) are not applicable. However, since it is a specific business development announcement, and there isn't a dedicated 'Business Development' or 'Pipeline Update' code, RNS serves as the best general regulatory/announcement category for this type of news release.
2021-05-20 English
New drug candidate for normal brain development in extremely premature infants
Regulatory Filings Classification · 99% confidence The document describes a research collaboration between Arctic Bioscience and Smerud Medical Research International regarding a new drug candidate for premature infants. It details the scientific rationale, development plans (including seeking orphan designation), and mentions future market potential. This is a corporate announcement detailing strategic business development and research progress, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general business update that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), it falls best under the general Regulatory Filings/Announcements category (RNS), as it is a material announcement to the market about company operations and pipeline development.
2021-05-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.